Literature DB >> 10404440

Atopic eczema: its social and financial costs.

A S Kemp1.   

Abstract

Atopic dermatitis is a disorder with considerable social and financial costs. A recent Australian study indicates that the family stress related to the care of a child with moderate or severe atopic dermatitis is significantly greater than that of care of children with insulin-dependent diabetes mellitus. The factors contributing to family stress include: sleep deprivation; loss of employment; time taken for care of atopic dermatitis; and financial costs. An estimate of the yearly financial costs for a family and community (which includes medical, hospital, direct costs of treatments and indirect costs from loss of employment), range from $A1142 per child per year with mild atopic dermatitis, to $A6099 per year for a child with severe atopic dermatitis. As the current prevalence of atopic dermatitis in Australia is 10-15%, this indicates a considerable financial burden on the community. It is possible that appropriate interventions directed to reducing trigger factors, may produce worthwhile savings, in addition to benefits for the individuals and families. Atopic dermatitis should not be regarded as a minor skin disorder but as a condition which has the potential to be a major handicap involving considerable personal, social and financial consequences both for the family and for the community.

Entities:  

Mesh:

Year:  1999        PMID: 10404440     DOI: 10.1046/j.1440-1754.1999.00343.x

Source DB:  PubMed          Journal:  J Paediatr Child Health        ISSN: 1034-4810            Impact factor:   1.954


  16 in total

1.  Cost-effectiveness model for a specific mixture of prebiotics in The Netherlands.

Authors:  I Lenoir-Wijnkoop; W M C van Aalderen; G Boehm; D Klaassen; A B Sprikkelman; M J C Nuijten
Journal:  Eur J Health Econ       Date:  2010-12-17

Review 2.  Cost-of-illness studies : a review of current methods.

Authors:  Ebere Akobundu; Jing Ju; Lisa Blatt; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 3.  The economics of topical immunomodulators for the treatment of atopic dermatitis.

Authors:  William Abramovits; Mark Boguniewicz; Amy S Paller; Diane L Whitaker-Worth; Mary M Prendergast; Michael Tokar; Kuo B Tong
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

4.  Overview of Reviews The prevention of eczema in infants and children: an overview of Cochrane and non-Cochrane reviews.

Authors:  Michelle Foisy; Robert J Boyle; Joanne R Chalmers; Eric L Simpson; Hywel C Williams
Journal:  Evid Based Child Health       Date:  2011-09-08

5.  Eczema, sleep, and behavior in children.

Authors:  Danny Camfferman; J Declan Kennedy; Michael Gold; A James Martin; Peter Winwood; Kurt Lushington
Journal:  J Clin Sleep Med       Date:  2010-12-15       Impact factor: 4.062

6.  [Economic aspects of allergies: status and prospects for Austria].

Authors:  Viktoria Stein; Thomas Dorner; Kitty Lawrence; Michael Kunze; Anita Rieder
Journal:  Wien Med Wochenschr       Date:  2007

Review 7.  Cost of illness of atopic dermatitis in children: a societal perspective.

Authors:  Andrew S Kemp
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 8.  Maternal prenatal and/or postnatal n-3 long chain polyunsaturated fatty acids (LCPUFA) supplementation for preventing allergies in early childhood.

Authors:  Anoja W Gunaratne; Maria Makrides; Carmel T Collins
Journal:  Cochrane Database Syst Rev       Date:  2015-07-22

9.  Hwangryunhaedoktang in adult patients with atopic dermatitis: a randomised, double-blind, placebo-controlled, two-centre trial--study protocol.

Authors:  Nam-Kwen Kim; Dong-Hyo Lee; Hyung-Sik Seo; Seung-Ho Sun; Yong-Leol Oh; Ji-Eun Kim; In-Hwan Yoon; Eun-Sung Seo; Gye-Seon Shim; Christopher Zaslawski
Journal:  BMC Complement Altern Med       Date:  2011-08-23       Impact factor: 3.659

10.  Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial.

Authors:  Shuba Rajashri Iyengar; Elizabeth G Hoyte; Angelica Loza; Salvatore Bonaccorso; David Chiang; Dale T Umetsu; Kari Christine Nadeau
Journal:  Int Arch Allergy Immunol       Date:  2013-06-27       Impact factor: 2.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.